Cargando…

Imaging in Alzheimer's disease

Neuroimaging in the early differential diagnosis of dementia has gained considerable interest over the last decade. From being used for exclusive purposes only, neuroimaging is now in the forefront of aiding in the diagnosis of Alzheimer's disease (AD), frontotemporal dementia, vascular dementi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Scheltens, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Les Laboratoires Servier 2009
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181915/ https://www.ncbi.nlm.nih.gov/pubmed/19585954

Ejemplares similares

Heterogeneity of Alzheimer’s disease: consequence for drug trials?
por: Devi, Gayatri, et al.
Publicado: (2018)

The plasma peptides of Alzheimer’s disease
por: Florentinus-Mefailoski, Angelique, et al.
Publicado: (2021)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
por: Prins, Niels D, et al.
Publicado: (2013)

The predictive value of normal EEGs in dementia due to Alzheimer’s disease
por: Briels, Casper T., et al.
Publicado: (2021)

Reproducibility of EEG functional connectivity in Alzheimer’s disease
por: Briels, Casper T., et al.
Publicado: (2020)

Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
por: Dubois, Bruno, et al.
Publicado: (2015)

The Alzheimer’s disease drug development landscape
por: van Bokhoven, Pieter, et al.
Publicado: (2021)

Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?
por: Galasko, Douglas, et al.
Publicado: (2013)

Early diagnosis of Alzheimer's disease: update on combining genetic and brain-imaging measures
por: Small, Gary W.
Publicado: (2000)

Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer's Disease
por: de Haan, Willem, et al.
Publicado: (2012)

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
por: Galasko, Douglas, et al.
Publicado: (2020)

Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
por: Schoonhoven, Deborah N., et al.
Publicado: (2022)

The discovery of Alzheimer's disease
por: Hippius, Hanns, et al.
Publicado: (2003)

Cost of Alzheimer's disease
por: Davidson, Michael, et al.
Publicado: (2000)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Clinical Features of Patients with Alzheimer's Disease and a History of Traumatic Brain Injury
por: van Amerongen, Suzan, et al.
Publicado: (2022)

Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease
por: Boon, Baayla D. C., et al.
Publicado: (2018)

Frontotemporal dementia to Alzheimer's disease
por: Silveri, Maria Caterina
Publicado: (2007)

Diagnosis and management of Alzheimer's disease
por: Burns, Alistair
Publicado: (2000)

Memory loss in Alzheimer's disease
por: Jahn, Holger
Publicado: (2013)

Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations
por: Hooghiemstra, Astrid M., et al.
Publicado: (2012)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Microbleeds are associated with depressive symptoms in Alzheimer's disease
por: Leeuwis, Anna E., et al.
Publicado: (2017)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Single-Subject Grey Matter Graphs in Alzheimer's Disease
por: Tijms, Betty M., et al.
Publicado: (2013)

The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
por: Jochemsen, Hadassa M, et al.
Publicado: (2014)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
por: Engels, Marjolein MA, et al.
Publicado: (2015)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life
por: Abheiden, Carolien N.H., et al.
Publicado: (2015)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease
por: Wollman, Daniel E., et al.
Publicado: (2003)

Vascular Factors and Cognitive Dysfunction in Alzheimer Disease
por: Pachalska, Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d3pr40kbcdipcj4pemg6agc9gu